GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (OTCPK:KNTPF) » Definitions » Total Long-Term Liabilities

KNTPF (Kintor Pharmaceutical) Total Long-Term Liabilities : $7.47 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Kintor Pharmaceutical's Total Long-Term Liabilities for the quarter that ended in Dec. 2024 was $7.47 Mil.


Kintor Pharmaceutical Total Long-Term Liabilities Historical Data

The historical data trend for Kintor Pharmaceutical's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Total Long-Term Liabilities Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial 26.64 30.32 34.69 26.10 7.47

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.69 38.37 26.10 15.12 7.47

Kintor Pharmaceutical Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Kintor Pharmaceutical Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintor Pharmaceutical Business Description

Traded in Other Exchanges
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.

Kintor Pharmaceutical Headlines